AstraZeneca Pharma Gets DCGI Nod To Import, Market Prostate Cancer Drug Olaparib Film-Coated Tablets
Mumbai: Pharma major, AstraZeneca Pharma India Limited said that it has received Import and Market permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Olaparib Film-Coated tablets 100 mg and 150 mg - additional indication.
Olaparib Film-Coated tablets 100 mg and 150 mg is additionally indicated as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene mutations (germline and/or somatic) who have progressed following a prior new hormonal agent, company said in a filing with BSE.
The receipt of this Import and Market permission paves way for the launch of Olaparib FilmCoated Tablets 100 mg and 150 mg (Lynparza) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses.
Read also: Oxford-AstraZeneca Covid-19 Vaccine Gets ICMR Nod To Begin Trials At KEM, Nair Hospitals
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!